Elevated levels of G-CSF, GM-CSF, and IL-13, which have therapeutic effects on AD, and IL-1RA, MIP-1α, RANTES, and IFN-γ, which are anticipated to improve AD symptoms, were observed following CB201 administration. The gene discussed is CSF2; the disease is Alzheimer disease.